Advanced Cancer Clinical Trial
Official title:
A Qualitative Study of Patient-Reported Outcomes (PRO)-Based Palliative and Hospice Care Practice: Integrating PROs and Decision Support Into an Electronic Record
The goal of this research study is to collect information to plan how to design a computer program for cancer patients receiving palliative care, their caregivers, and doctors and nurses who work in palliative care. Researchers want to learn how to make this program practical for use by future patients, caregivers, doctors, and nurses.
The Computer Program:
In this study, researchers will interview cancer patients receiving palliative care, their
caregivers, and doctors and nurses who work in palliative care.
The computer program will be designed to help doctors and nurses monitor the symptoms of
patients. The program will also be designed to help doctors and nurses make decisions about
how to care for patients.
Interview Session:
If you agree to take part in this study, you will be interviewed by a research staff member.
The study chair may also attend the interview. The interview will be held at the Palliative
Care outpatient clinic.
The interview session will be done in 3 steps, which are described below. Each step will
take about 10 minutes.
First, you will read questionnaires about patient symptoms. These questionnaires are drafts
of the ones that will be included in the software program.
You will then look at a draft of the computer program's layout.
Last, you will be interviewed. You will be asked to discuss your experiences as a patient or
caregiver in reporting symptoms and health status to doctors and nurses. You will also be
asked to discuss what might make the program more usable.
During the interview, you may also be asked to answer sample questions on the draft
questionnaires and discuss how readable you think the questions are. For example, you will
discuss your opinion about the font size, text placement, and color scheme.
Study Data:
The interview session will be audio-taped. To protect your confidentiality, only your first
name will be used during the interview session. Patients and their caregivers will also be
interviewed separately to protect privacy.
Patient responses will not be disclosed to caregivers, and caregiver responses will not be
disclosed to patients. The patient's palliative care doctor will be told, however, if
patients or caregivers show signs of emotional difficulties.
When the audio recording is transcribed (typed) by the research staff, all names will be
coded so that no one can be identified by name. The audio recordings will be stored in
password-protected files that are available only to the study chair and staff.
After the results of the study are published, the audio recordings will be destroyed by the
study staff.
Length of Study:
Your study participation will be over after the interview session.
This is an investigational study.
Up to 26 participants will be enrolled in this study. This includes up to 9 patients and 9
caregivers in this part of the study, and up to 4 doctors and 4 nurses in a second part of
the study. All will be enrolled at M. D. Anderson.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 |